Abstract
Genetic alterations in K-ras and p53 are thought to be critical in pancreatic cancer development and progression. However, K-ras and p53 expression in pancreatic adenocarcinoma have not been systematically examined in The Cancer Genome Atlas (TCGA) Data Portal. Information regarding K-ras and p53 alterations, mRNA expression data, and protein/protein phosphorylation abundance was retrieved from The Cancer Genome Atlas (TCGA) databases, and analyses were performed by the cBioPortal for Cancer Genomics. The mutual exclusivity analysis showed that events in K-ras and p53 were likely to co-occur in pancreatic adenocarcinoma (Log odds ratio = 1.599, P = 0.006). The graphical summary of the mutations showed that there were hotspots for protein activation. In the network analysis, no solid association between K-ras and p53 was observed in pancreatic adenocarcinoma. In the survival analysis, neither K-ras nor p53 were associated with both survival events. As in the data mining study in the TCGA databases, our study provides a new perspective to understand the genetic features of K-ras and p53 in pancreatic adenocarcinoma.
Highlights
Pancreatic cancer (PC) happens when pancreatic cells start to proliferate without control and form a mass
As far as we know, this is the first data mining study to explore the relationship between alterations of K-ras and p53 and patient prognosis in The Cancer Genome Atlas (TCGA) databases
Shin et al.[6] verified that K-ras mutation alone was related with patients’ survival, and that GAT subtype had the closest relationship with survival among the Korean population. These findings suggest that K-ras mutation has a different prognosis value of pancreatic adenocarcinoma in different geographic locations and populations
Summary
Pancreatic cancer (PC) happens when pancreatic cells start to proliferate without control and form a mass. As the most frequent type of PC, pancreatic adenocarcinoma takes the largest proportion 85% of all cases, which is usually equivalent to the expression "pancreatic cancer". The global annual incidence rate for PC is about 8/100,000 persons.[1] Recently it is reported that the treatment is promising in the near future.[2] as the overall 5-year survival rate was only 5%, PC remains one of the most lethal cancers [3,4]. An overall reduction in cancer-related mortality has occurred among lung, breast, colorectal and prostate cancer over the last few decades.[5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
